Patients who had an increase in the frequency of CD21- B-cells during ICI treatment were less likely to respond to ICI treatment, as indicated by DCR in univariable (OR=0.11, 95%CI=0.02-0.72, p=0.021) and multivariable analyses adjusted for tumor type (OR=0.05, 95%CI=0.00-0.67, p=0.024). This evidence concerns the gene CR2 and neoplasm.